Share class: Concord Biotech Limited

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 10,46,16,204 2,60,93,471 ( 24.94 %) 0 24.94 %

Major shareholders: Concord Biotech Limited

NameEquities%Valuation
28.84 %
3,01,69,524 28.84 % 385 M ₹
9.547 %
99,87,636 9.547 % 128 M ₹
Aryavir Jhunjhunwala Discretionary Trust
8.029 %
83,99,754 8.029 % 107 M ₹
Aryaman Jhunjhunwala Discretionary Trust
8.029 %
83,99,754 8.029 % 107 M ₹
Nishtha Jhunjhunwala Discretionary Trust
8.029 %
83,99,732 8.029 % 107 M ₹
Sudman Consultants LLP
4.542 %
47,52,000 4.542 % 61 M ₹
1575773 Ontario, Inc.
2 %
20,92,325 2 % 27 M ₹
1.934 %
20,23,219 1.934 % 26 M ₹
DSP Asset Managers Pvt. Ltd.
1.741 %
18,21,767 1.741 % 23 M ₹
1.201 %
12,56,432 1.201 % 16 M ₹
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░

Breakdown by shareholder type

Individuals42.84%
Other31.74%
Institutional4.48%
Unknown20.94%

Based on 1000 largest holdings

Geographical origin of shareholders

Individuals
42.84%
India
34.2%
United States
2%
United Arab Emirates
0.01%

Based on 1000 largest holdings

Logo Concord Biotech Limited
Concord Biotech Limited is an India-based research and development driven biopharma company. The Company is engaged in the research and development, manufacturing, marketing, and selling of pharmaceutical products. The Company manufactures active pharmaceutical ingredients (API) through fermentation and semi-synthetic process and finished formulations. The Company’s offerings span both bio-pharmaceutical APIs and formulations across therapeutic areas like immunosuppressants oncology, anti-infectives nephrology, and critical care. Its portfolio also includes fermentation-based APIs in anti-bacterial, anti-fungal, and other therapeutic segments. Its API products include Mycophenolate Mofetil, Mycophenolate Sodium, Cyclosporine, Sirolimus, Pimecrolimus, Voclosporin, Mupirocin, Mupirocin Calcium, Vancomycin Hydrochloride, Teicoplanin, Polymyxin B Sulfate, Fidaxomicin, Anidulafungin. Its API products under development include Daptomycin, Epirubicin, Idarubicin, and Pirarubicin.
Employees
1,571
SPRING SALE -40%: The Best Tools Reserved for Subscribers to Identify Tomorrow's Top Investments!
d
:
:
BENEFIT NOW